The Digestive Disease Week conference in San Diego unveiled compelling new analysis from a recent Phase 3 clinical trial. The findings suggest that a live biotherapeutic, primarily used to prevent the recurrence of Clostridioides difficile infection, may also enhance mental health parameters, creating a significant correlation with alterations in the gut’s microbiome and metabolome. Patients treated with fecal microbiota live-jslm, otherwise known as RBL or Rebyota, were reported to exhibit progressive improvements in mental health-related quality of life in comparison to placebo recipients, as per the PUNCH CD3 trial’s exploratory data.
These positive outcomes were noted even among certain participants who dealt with recurrent infections, indicating the broad-reaching potential of this approach. Dr Paul Feuerstadt, Associate Clinical Professor of Medicine at Yale School of Medicine and current gastroenterologist at PACT Gastroenterology Center, called the revelations a stepping stone in understanding recurrent C. difficile and exploring broader applications. He suggested the possibility of modifying a patient’s microbial composition to improve both their physical and emotional health by defining the specific dysbiosis for a given condition.
The Cdiff32 questionnaire, which measures physical, mental, and social impacts of infection, was the tool used to gauge patient-reported outcomes. It surfaced that RBL responders exhibited greater improvements in mental domain scores versus those responding to placebo. Microbiota changes were correlated with quality of life scores using a multivariate recursive partitioning analysis technique.
The findings highlighted that patients felt better with increases in Bacteroides and Clostridia and decreases in Gammaproteobacteria and Bacilli. The microbiome and bile acid profiles were scrutinized using genomic sequencing and liquid chromatography mass spectrometry. Participants whose profiles leaned towards increased levels of Clostridia and Bacteroidia, decreased levels of Gammaproteobacteria and Bacilli, and a shift toward secondary bile acids were noted to have improved mental health scores.
Dr. Feuerstadt posits that understanding this close relationship between the microbiota and mood, affected by gut organism-produced metabolome, presents potential means to affect people’s overall outlook and emotional wellbeing. he underscores the dual approach required for C. difficile treatment—antimicrobials to manage the infection and microbiota restoration to avoid its recurrence. However, the promising part remains the patient’s improved quality of life, attributed to these microbiota changes.
This clear correlation between clinically measurable changes and the patient’s subjective experiences could be a breeding ground for future research in the field of Infection Prevention.